Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio – FiercePharma
FiercePharma |
Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
FiercePharma Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio. by Tracy Staton |. Mar 23, 2017 4:55pm. Pfizer HQ. Pfizer paid $850 million up front to Merck KGaA to set up a cancer immunotherapy partnership, and Thursday's FDA … FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell … Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy … Avelumab: First Drug Ever Approved for Merkel Cell Carcinoma |
